Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant HDL Kinetics in Abdominal Obesity
NCT00408148Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in obesity and dyslipidemia comparing Rimonabant 20 mg with Placebo (2 arms). Primary endpoint: Fractional Catabolic Rate of HDL ApoA-I at 12 months. Started Oct 2006; status: terminated.
02
Drugs
rimonabant
03
Conditions
obesitydyslipidemia
Beyond the preview
Go deeper on NCT00408148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408148.